Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (211-220 of 1,124) with videos related to

Pageof 113
Sort By:
The Journal of Urology|February 26, 2020
Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate CancerFred Saad, Neil Fleshner, Tom Pickles, et al.
JAMA Oncology|May 9, 2024
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A ReviewMaha Hussain, Karim Fizazi, Neal D Shore, et al.
BJU International|May 31, 2008
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisoneFred Saad, Dean Ruether, Scott Ernst, et al.
Journal of Immunological Methods|June 26, 2009
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patientsPhilippe O Gannon, Alexis O Poisson, Nathalie Delvoye, et al.
Cell and Tissue Banking|December 28, 2011
Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomyFadi Brimo, Kanishka Sircar, Simone Chevalier, et al.
The Lancet. Oncology|January 1, 2022
Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' replyFred Saad, Peter De Porre, Sabine Brookman-May, et al.
Andrologia|April 14, 2021
The interaction between inflammation, urinary symptoms and erectile dysfunction in early-stage prostate cancer treated with brachytherapyAlexandre Alcaidinho, David-Dan Nguyen, Guila Delouya, et al.
Cancers|October 14, 2022
Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 DichlorideKevin Kaulanjan, Johanna Dahan, Cédric Charrois-Durand, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 27, 2017
Maximal testosterone suppression in the management of recurrent and metastatic prostate cancerLaurence Klotz, Rodney H Breau, Loretta L Collins, et al.
Cancers|April 30, 2021
Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and MortalitySylvie Clairefond, Véronique Ouellet, Benjamin Péant, et al.
Pageof 113

Showing results (211-220 of 1,124) with videos related to

Sort By:
Pageof 113
The Journal of Urology|February 26, 2020
Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate CancerFred Saad, Neil Fleshner, Tom Pickles, et al.
JAMA Oncology|May 9, 2024
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A ReviewMaha Hussain, Karim Fizazi, Neal D Shore, et al.
BJU International|May 31, 2008
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisoneFred Saad, Dean Ruether, Scott Ernst, et al.
Journal of Immunological Methods|June 26, 2009
Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patientsPhilippe O Gannon, Alexis O Poisson, Nathalie Delvoye, et al.
Cell and Tissue Banking|December 28, 2011
Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomyFadi Brimo, Kanishka Sircar, Simone Chevalier, et al.
The Lancet. Oncology|January 1, 2022
Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' replyFred Saad, Peter De Porre, Sabine Brookman-May, et al.
Andrologia|April 14, 2021
The interaction between inflammation, urinary symptoms and erectile dysfunction in early-stage prostate cancer treated with brachytherapyAlexandre Alcaidinho, David-Dan Nguyen, Guila Delouya, et al.
Cancers|October 14, 2022
Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 DichlorideKevin Kaulanjan, Johanna Dahan, Cédric Charrois-Durand, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 27, 2017
Maximal testosterone suppression in the management of recurrent and metastatic prostate cancerLaurence Klotz, Rodney H Breau, Loretta L Collins, et al.
Cancers|April 30, 2021
Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and MortalitySylvie Clairefond, Véronique Ouellet, Benjamin Péant, et al.
Pageof 113